Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis
Authors:
- Iain L.O. BuxtonIBIain L.O. Buxton
- Nucharee YokdangNYNucharee Yokdang
- Robert M. MatzRMRobert M. Matz
- 1 May 2010
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 291 (2) , 131-141
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (HD053028)
- National Institutes of Health (T32 CA09563)
This publication has 169 references indexed in Scilit:
- Adenosine Receptors and Cancer2009
- Nucleoside diphosphate kinase (NDPK, NM23, AWD): recent regulatory advances in endocytosis, metastasis, psoriasis, insulin release, fetal erythroid lineage and heart failure; translational medicine exemplifiedMolecular and Cellular Biochemistry, 2009
- Cancer survival in five continents: a worldwide population-based study (CONCORD)The Lancet Oncology, 2008
- Clinical biomarkers of angiogenesis inhibitionCancer and Metastasis Reviews, 2008
- P2 receptors in cardiovascular regulation and diseasePurinergic Signalling, 2007
- Autocrine VEGF Signaling Is Required for Vascular HomeostasisCell, 2007
- Molecular Modeling of the Human P2Y2 Receptor and Design of a Selective Agonist, 2‘-Amino-2‘-deoxy-2-thiouridine 5‘-TriphosphateJournal of Medicinal Chemistry, 2007
- Measurement of adenine nucleotides in plasmaLuminescence, 2003
- The Hallmarks of CancerCell, 2000
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996